Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Evidence- |
RCV000257604 | SCV000323382 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 1 | 2016-10-18 | reviewed by expert panel | curation | Variant allele predicted to encode a truncated non-functional protein. |
Consortium of Investigators of Modifiers of BRCA1/2 |
RCV000257604 | SCV000325204 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 1 | 2015-10-02 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV000509880 | SCV000608096 | pathogenic | Hereditary cancer-predisposing syndrome | 2015-10-29 | criteria provided, single submitter | clinical testing | The p.Y655* pathogenic mutation (also known as c.1965C>A), located in coding exon 9 of the BRCA1 gene, results from a C to A substitution at nucleotide position 1965. This changes the amino acid from a tyrosine to a stop codon within coding exon 9. This alteration has been reported in one HBOC family from France and one from northern Spain (Lecarpentier J et al. Breast Cancer Res. 2012; 14(4):R99; Blay P et al. BMC Cancer 2013; 13:243). Since premature stop codons are typically deleterious in nature, this alteration is interpreted as a disease-causing mutation (ACMG Recommendations for Standards for Interpretation and Reporting of Sequence Variations. Revision 2007. Genet Med. 2008;10:294). |
Molecular Oncology, |
RCV000257604 | SCV005061280 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 1 | 2021-05-24 | no assertion criteria provided | case-control |